SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2015 second quarter, ended March 31, 2015.
According to SurModics’ President and Chief Executive Officer Gary Maharaj, “With revenue rising 6% over year ago results, SurModics posted strong performance in the fiscal second quarter, as we concurrently continued our transformation to a whole products solution provider. As planned, we increased our investment in the SurModics SurVeil™ Drug Coated Balloon product as we continued the GLP (Good Laboratory Practice) pre-clinical study, and started preparation for our first-in-human clinical trial.”
Second Quarter Revenue and Earnings Summary
GAAP revenue for the fiscal 2015 second quarter totaled $14.4 million, compared with $13.6 million in the fiscal 2014 second quarter. Even with investments in transformative growth, the Company’s operating margin was a healthy 27%.
Diluted GAAP earnings per share in the second quarter of fiscal 2015 were $0.23 compared with $0.18 in the prior-year period. The second quarter fiscal 2015 earnings include $0.04 per share gain associated with one of our investments. The 2014 second quarter earnings included a $0.04 per share one-time, non-cash charge related to amendments to board of directors’ equity compensation. On a non-GAAP comparative basis, earnings per share decreased 14% in the second quarter of fiscal 2015 from $0.22 to $0.19 per share. This decrease was primarily from planned research and development expenses as well as increased legal and professional services costs.
Medical Device Segment
The Medical Device business unit accounts for approximately three-quarters of the Company’s revenue. This unit, which includes hydrophilic coatings and device drug delivery technologies, posted revenue of $10.6 million in the second quarter of fiscal 2015, increasing 1% from the year-ago period. Second quarter 2015 hydrophilic coating royalty revenue was $7.2 million, increasing 2% with the year-year period. We continued to see diversification of our hydrophilic portfolio as for the second consecutive quarter peripheral royalties were the leading royalty segment. Medical Device generated $4.7 million of operating income during the second quarter, decreasing 11% from the year-ago period; operating income was affected by higher planned costs for drug coated balloon development.
Additionally, two medical device customers launched new products utilizing SurModics hydrophilic coatings in the 2015 second quarter.
Drug Coated Balloon Update
As noted above, SurModics continued its SurVeil Drug Coated Balloon product GLP study during the second quarter of fiscal 2015. According to Maharaj, “We continue to be on track to begin a first-in-human clinical trial this fiscal year. We are also encouraged by the acceptance of drug coated balloons as an important therapeutic modality to treat peripheral artery disease, as well as by recent improved reimbursement.”
In Vitro Diagnostics Segment
The In Vitro Diagnostics (IVD) business unit accounts for approximately one-quarter of the Company’s revenue. Revenue for the second quarter of fiscal 2015 totaled $3.9 million, increasing 23% from the year-ago period. The prior-year quarter was adversely impacted by a few customers’ inventory rebalancing. The IVD business unit generated $0.9 million of operating income in the second quarter of fiscal 2015, compared with $0.6 million in the year-ago period. Operating income benefited from increased revenue.
Said Maharaj, “We are pleased to see the strength in marketplace demand for our IVD offerings. This represents IVD’s fourth consecutive quarter of growth – and the 17th out of the last 18 quarters.”
Balance Sheet and Cash Flow
As of March 31, 2015, the Company had $49.1 million of cash and investments and no outstanding debt. SurModics generated cash from operating activities of $6.8 million in the first six months of fiscal 2015, compared with $5.9 million in the prior-year six-month period. Capital expenditures and share repurchases totaled $0.2 million and $20.0 million, respectively, for the six-month period. The $20.0 million of share repurchases resulted from the first quarter fiscal 2015 accelerated share repurchase program that was announced in SurModics’ fourth quarter fiscal 2014 earnings release.
Fiscal 2015 Outlook
According to Maharaj, “We look forward to sustained progress in the second half of fiscal 2015.”
The Company is reaffirming its previously stated revenue, earnings per share and operating cash flow guidance for fiscal 2015. SurModics expects full-year revenue to be in the range of $57.0 to $60.0 million, and diluted GAAP earnings to be in the range of $0.85 per share to $0.95 per share. The fiscal 2015 earnings per share guidance includes: an increase of approximately 5% to 7% in research and development investment over fiscal 2014 levels, primarily related to the drug coated balloon program; an assumed 13.3 million diluted shares outstanding; and a 33.0% to 35.0% income tax rate. The Company’s earnings per share and income tax rate guidance exclude the impact of any strategic investment or short-term investment gains and losses. GAAP cash flow from operating activities is expected to range between $16.5 million and $18.0 million for fiscal 2015, unchanged from prior guidance. SurModics is lowering its planned capital expenditures estimate for fiscal 2015 to a range between $1.7 million and $2.2 million, compared to previous guidance of $2.2 million to $2.5 million.
Live Webcast
SurModics will host a webcast at 4 p.m. CT (5 p.m. ET) today to discuss second quarter results. To access the webcast, go to the investor relations portion of the Company’s website at www.surmodics.com and click on the webcast icon. A replay of the second quarter conference call will be available by dialing 888-203-1112 and entering conference call ID passcode 8699575. The audio replay will be available beginning at 7 p.m. CT on Thursday, April 30, 2015, until 7 p.m. CT on Thursday, May 7, 2015.
About SurModics SurVeil™ Drug Coated Balloon
SurModics SurVeil Drug Coated Balloon is a product designed to treat peripheral arterial disease. SurModics SurVeil Drug Coated Balloon is a development stage product and is currently not approved for sale in any country. Following completion of the GLP pre-clinical study, we plan to seek regulatory approval to initiate a first-in-human trial using SurModics SurVeil Drug Coated Balloon in late fiscal 2015.
About SurModics, Inc.
SurModics partners with the world’s leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. Our mission is to be a trusted partner to our customers by providing the most advanced surface modification technologies and in vitro diagnostic chemical components that help enhance the well-being of patients. The company’s core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility characteristics and components for in vitro diagnostic test kits and microarrays. SurModics’ strategy is to build on the product and technical leadership within these fields, and expand the core offerings to generate opportunities for longer term sustained growth. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit www.surmodics.com. The content of SurModics’ website is not part of this press release or part of any filings that the Company makes with the SEC.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or current facts, including statements about beliefs and expectations regarding the Company’s capital needs and its performance in the near- and long-term, including our revenue, earnings and cash flow expectations for fiscal 2015, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including (1) our ability to successfully develop, obtain regulatory approval for, and commercialize our SurVeil Drug Coated Balloon product; (2) our reliance on third parties (including our customers and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies; (3) our ability to achieve our corporate goals; (4) our ability to successfully identify and acquire target companies or achieve expected benefits from acquisitions that are consummated; (5) possible adverse market conditions and possible adverse impacts on our cash flows, and (6) the factors identified under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2014, and updated in our subsequent reports filed with the SEC. These reports are available in the Investors section of our website at www.surmodics.com and at the SEC website at www.sec.gov. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.
Use of Non-GAAP Financial Information
In addition to reporting financial results in accordance with generally accepted accounting principles, or GAAP, SurModics is reporting non-GAAP financial results including non-GAAP net income, non-GAAP diluted net income per share, and EBITDA. We believe that these non-GAAP measures provide meaningful insight into our operating performance excluding certain event-specific matters, and provide an alternative perspective of our results of operations. We use non-GAAP measures, including those set forth in this release, to assess our operating performance and to determine payout under our executive compensation programs. We believe that presentation of certain non-GAAP measures allows investors to review our results of operations from the same perspective as management and our board of directors and facilitates comparisons of our current results of operations. The method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the methods used by other companies. Non-GAAP results should not be regarded as a substitute for corresponding GAAP measures but instead should be utilized as a supplemental measure of operating performance in evaluating our business. Non-GAAP measures do have limitations in that they do not reflect certain items that may have a material impact on our reported financial results. As such, these non-GAAP measures should be viewed in conjunction with both our financial statements prepared in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to the comparable GAAP results provided for the specific periods presented, which are attached to this release.
SurModics, Inc. and Subsidiaries | ||||||||||||||||
| Three Months Ended March 31, | Six Months Ended March 31, | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| (Unaudited) | (Unaudited) | |||||||||||||||
| Revenue: | ||||||||||||||||
| Royalties and license fees | $ | 7,383 | $ | 7,329 | $ | 14,658 | $ | 14,794 | ||||||||
| Product sales | 5,651 | 5,165 | 11,498 | 10,565 | ||||||||||||
| Research and development | 1,381 | 1,110 | 2,464 | 2,128 | ||||||||||||
| Total revenue | 14,415 | 13,604 | 28,620 | 27,487 | ||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| Product costs | 1,955 | 1,696 | 3,857 | 3,700 | ||||||||||||
| Research and development | 4,403 | 4,134 | 7,979 | 7,833 | ||||||||||||
| Selling, general and administrative | 4,125 | 4,294 | 7,818 | 8,145 | ||||||||||||
| Total operating costs and expenses | 10,483 | 10,124 | 19,654 | 19,678 | ||||||||||||
| Operating income | 3,932 | 3,480 | 8,966 | 7,809 | ||||||||||||
| Other income: | ||||||||||||||||
| Investment income, net | 56 | 66 | 113 | 152 | ||||||||||||
| Other income, net | 543 | 125 | 536 | 806 | ||||||||||||
| Other income | 599 | 191 | 649 | 958 | ||||||||||||
| Income before income taxes | 4,531 | 3,671 | 9,615 | 8,767 | ||||||||||||
| Income tax provision | (1,480 | ) | (1,212 | ) | (2,950 | ) | (2,678 | ) | ||||||||
| Net income | $ | 3,051 | $ | 2,459 | $ | 6,665 | $ | 6,089 | ||||||||
| Basic net income per share | $ | 0.24 | $ | 0.18 | $ | 0.51 | $ | 0.45 | ||||||||
| Diluted net income per share | $ | 0.23 | $ | 0.18 | $ | 0.50 | $ | 0.44 | ||||||||
| Weighted average number of shares outstanding: | ||||||||||||||||
| Basic | 12,944 | 13,538 | 13,092 | 13,658 | ||||||||||||
| Diluted | 13,207 | 13,824 | 13,365 | 13,925 | ||||||||||||
SurModics, Inc. and Subsidiaries | ||||||||
March 31, | September 30, | |||||||
| (Unaudited) | ||||||||
| Assets | ||||||||
| Cash and short-term investments | $ | 49,134 | $ | 46,551 | ||||
| Accounts receivable | 4,927 | 4,751 | ||||||
| Inventories | 3,195 | 2,817 | ||||||
| Other current assets | 2,508 | 1,145 | ||||||
| Current assets of discontinued operations | ― | 16 | ||||||
| Total current assets | 59,764 | 55,280 | ||||||
| Property and equipment, net | 12,419 | 13,133 | ||||||
| Long-term investments | ― | 16,823 | ||||||
| Other assets | 18,509 | 19,653 | ||||||
| Total assets | $ | 90,692 | $ | 104,889 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current liabilities | $ | 3,554 | $ | 4,022 | ||||
| Current liabilities of discontinued operations | ― | 45 | ||||||
| Total current liabilities | 3,554 | 4,067 | ||||||
| Other liabilities | 1,958 | 2,071 | ||||||
| Total stockholders’ equity | 85,180 | 98,751 | ||||||
| Total liabilities and stockholders’ equity | $ | 90,692 | $ | 104,889 | ||||
SurModics, Inc. and Subsidiaries | ||||||||
Six Months Ended | ||||||||
| 2015 | 2014 | |||||||
| (Unaudited) | ||||||||
| Operating Activities: | ||||||||
| Net income | $ | 6,665 | $ | 6,089 | ||||
| Depreciation and amortization | 1,389 | 1,380 | ||||||
| Stock-based compensation | 1,211 | 2,462 | ||||||
| Gains on sales of available-for-sale securities and strategic investments | (515 | ) | (806 | ) | ||||
| Net other operating activities | 313 | (822 | ) | |||||
| Change in operating assets and liabilities: | ||||||||
| Accounts receivable | (176 | ) | (278 | ) | ||||
| Accounts payable and accrued liabilities | (609 | ) | (1,770 | ) | ||||
| Income taxes | (825 | ) | (559 | ) | ||||
| Net change in other operating assets and liabilities | (623 | ) | 240 | |||||
| Net cash provided by operating activities from continuing operations | 6,830 | 5,936 | ||||||
| Investing Activities: | ||||||||
| Purchases of property and equipment | (163 | ) | (798 | ) | ||||
| Cash transferred to discontinued operations | (45 | ) | (13 | ) | ||||
| Net other investing activities | (167 | ) | 495 | |||||
| Net cash used in investing activities from continuing operations | (375 | ) | (316 | ) | ||||
| Financing Activities: | ||||||||
| Repurchase of common stock | (20,000 | ) | (12,544 | ) | ||||
| Purchases of common stock to pay employee taxes | (741 | ) | (1,114 | ) | ||||
| Net other financing activities | 790 | 987 | ||||||
| Net cash used in financing activities from continuing operations | (19,951 | ) | (12,671 | ) | ||||
| Net cash used in continuing operations | (13,496 | ) | (7,051 | ) | ||||
| Discontinued operations: | ||||||||
| Net cash used in operating activities | (45 | ) | (13 | ) | ||||
| Net cash provided by financing activities | 45 | 13 | ||||||
| Net cash used in discontinued operations | ― | ― | ||||||
| Net change in cash and cash equivalents | (13,496 | ) | (7,051 | ) | ||||
| Cash and Cash Equivalents: | ||||||||
| Beginning of period | 43,511 | 15,495 | ||||||
| End of period | $ | 30,015 | $ | 8,444 | ||||
SurModics, Inc. and Subsidiaries | |||||||||||||||
(Unaudited) | |||||||||||||||
| Three Months Ended March 31, | |||||||||||||||
| 2015 | 2014 | % Change | |||||||||||||
| Revenue | % of Total | % of Total | |||||||||||||
| Medical Device | $ | 10,562 | 73.3 | % | $ | 10,482 | 77.0 | % | 0.8 | % | |||||
| In Vitro Diagnostics | 3,853 | 26.7 | 3,122 | 23.0 | 23.4 | ||||||||||
| Total revenue | $ | 14,415 | 100.0 | % | $ | 13,604 | 100.0 | % | 6.0 | % | |||||
| Six Months Ended March 31, | |||||||||||||||
| 2015 | 2014 | % Change | |||||||||||||
| Revenue | % of Total | % of Total | |||||||||||||
| Medical Device | $ | 21,198 | 74.1 | % | $ | 21,031 | 76.5 | % | 0.8 | % | |||||
| In Vitro Diagnostics | 7,422 | 25.9 | 6,456 | 23.5 | 15.0 | ||||||||||
| Total revenue | $ | 28,620 | 100.0 | % | $ | 27,487 | 100.0 | % | 4.1 | % | |||||
Three Months Ended | Six Months Ended | |||||||||||||||
| 2015 | 2014 | 2015 | 2014 | |||||||||||||
| Operating Income | ||||||||||||||||
| Medical Device | $ | 4,696 | $ | 5,282 | $ | 10,212 | $ | 10,610 | ||||||||
| In Vitro Diagnostics | 931 | 633 | 2,028 | 1,303 | ||||||||||||
| Corporate | (1,695 | ) | (2,435 | ) | (3,274 | ) | (4,104 | ) | ||||||||
| Total operating income | $ | 3,932 | $ | 3,480 | $ | 8,966 | $ | 7,809 | ||||||||
SurModics, Inc. and Subsidiaries | |||||||||||||||
(Unaudited) | |||||||||||||||
As Reported | Adjustments | Adjusted | |||||||||||||
| Revenue | |||||||||||||||
| Royalties and license fees | $ | 7,383 | $ | 7,383 | |||||||||||
| Product sales | 5,651 | 5,651 | |||||||||||||
| Research and development | 1,381 | 1,381 | |||||||||||||
| Total revenue | $ | 14,415 | $ | 14,415 | |||||||||||
| Operating income | $ | 3,932 | $ | 3,932 | |||||||||||
| Net income | $ | 3,051 | $ | (523 | ) | (3) | $ | 2,528 | |||||||
| Diluted net income per share(4) | $ | 0.23 | $ | 0.19 | |||||||||||
| (1) Reflects operating results in accordance with U.S. generally accepted accounting principles (GAAP). | |||||||||||||||
| (2) Adjusted Non-GAAP considers an adjustment to reflect a $523 reduction in net investment income associated with the sale of Intersect ENT shares. The adjustment to reduce net investment income did not generate a tax benefit as there was an offsetting establishment of a capital loss valuation reserve. | |||||||||||||||
| (3) Reflects the impact of the net investment income adjustment noted in (2) above. | |||||||||||||||
| (4) Diluted net income per share is calculated using the diluted weighted average shares outstanding for the period presented. | |||||||||||||||
SurModics, Inc. and Subsidiaries | |||||||||||||||
(Unaudited) | |||||||||||||||
As Reported | Adjustments | Adjusted | |||||||||||||
| Revenue | |||||||||||||||
| Royalties and license fees | $ | 7,329 | $ | 7,329 | |||||||||||
| Product sales | 5,165 | 5,165 | |||||||||||||
| Research and development | 1,110 | 1,110 | |||||||||||||
| Total revenue | $ | 13,604 | $ | 13,604 | |||||||||||
| Operating income | $ | 3,480 | $ | 914 | (3) | $ | 4,394 | ||||||||
| Net income | $ | 2,459 | $ | 580 | (4) | $ | 3,039 | ||||||||
| Diluted net income per share(5) | $ | 0.18 | $ | 0.22 | |||||||||||
| (1) Reflects operating results in accordance with U.S. generally accepted accounting principles (GAAP). | |||||||||||||||
| (2) Adjusted Non-GAAP amounts consider adjustments to reflect a $914 reduction to operating expenses associated with acceleration of Board of Director stock-based compensation awards and adjustment to the income tax provision utilizing a 36.5% incremental effective tax rate. | |||||||||||||||
| (3) Reflects the pre-tax impact of the operating expense adjustment noted in (2) above. | |||||||||||||||
| (4) Adjusted to reflect the adjustment noted in (2) above. | |||||||||||||||
| (5) Diluted net income per share is calculated using the diluted weighted average shares outstanding for the period presented. | |||||||||||||||
SurModics, Inc. and Subsidiaries | |||||||||||||||
(Unaudited) | |||||||||||||||
As Reported | Adjustments | Adjusted | |||||||||||||
| Revenue | |||||||||||||||
| Royalties and license fees | $ | 14,658 | $ | 14,658 | |||||||||||
| Product sales | 11,498 | 11,498 | |||||||||||||
| Research and development | 2,464 | 2,464 | |||||||||||||
| Total revenue | $ | 28,620 | $ | 28,620 | |||||||||||
| Operating income | $ | 8,966 | $ | 8,966 | |||||||||||
| Net income | $ | 6,665 | $ | (724 | ) | (3) | $ | 5,941 | |||||||
| Diluted net income per share(4) | $ | 0.50 | $ | 0.44 | |||||||||||
| (1) Reflects operating results in accordance with U.S. generally accepted accounting principles (GAAP). | |||||||||||||||
| (2) Adjusted Non-GAAP amount considers adjustments to net investment income and the income tax provision for a discrete income tax benefit in the period presented as noted in (3) below. | |||||||||||||||
| (3) Adjusted to reflect a $523 reduction in net investment income associated with the sale of Intersect ENT shares. The adjustment to reduce net investment income did not generate a tax benefit as there was an offsetting establishment of a capital loss valuation reserve. In addition, the income tax provision is adjusted to reflect discrete income tax benefits of $201 associated with the December 2014 signing of the Tax Increase Prevention Act of 2014 which retroactively reinstated federal R&D income tax credits for calendar 2014. | |||||||||||||||
| (4) Diluted net income per share is calculated using the diluted weighted average shares outstanding for the period presented. | |||||||||||||||
SurModics, Inc. and Subsidiaries | |||||||||||||||
(Unaudited) | |||||||||||||||
As Reported | Adjustments | Adjusted | |||||||||||||
| Revenue | |||||||||||||||
| Royalties and license fees | $ | 14,794 | $ | 14,794 | |||||||||||
| Product sales | 10,565 | 10,565 | |||||||||||||
| Research and development | 2,128 | 2,128 | |||||||||||||
| Total revenue | $ | 27,487 | $ | 27,487 | |||||||||||
| Operating income | $ | 7,809 | $ | 914 | (3) | $ | 8,723 | ||||||||
| Net income | $ | 6,089 | $ | (101 | ) | (4) | $ | 5,988 | |||||||
| Diluted net income per share(5) | $ | 0.44 | $ | 0.43 | |||||||||||
| (1) Reflects operating results in accordance with U.S. generally accepted accounting principles (GAAP). | |||||||||||||||
| (2) Adjusted Non-GAAP amounts consider adjustments to reduce operating expenses by $914 associated with acceleration of Board of Director stock-based compensation awards and a $681 reduction in net investment income associated with a contingent milestone payment related to the sale of Vessix Vascular shares in fiscal 2013. The income tax provision includes an adjustment associated with the stock-based compensation awards utilizing a 36.5% incremental effective tax rate. The net investment income adjustment did not generate a tax benefit as there was an offsetting establishment of a capital loss valuation reserve. | |||||||||||||||
| (3) Reflects the pre-tax impact of the operating expense adjustment noted in (2) above. | |||||||||||||||
| (4) Adjusted to reflect the adjustment noted in (2) above. | |||||||||||||||
| (5) Diluted net income per share is calculated using the diluted weighted average shares outstanding for the period presented. | |||||||||||||||
Contacts:
Andy LaFrence, 952-500-7000
Vice President of
Finance and Chief Financial Officer
